Compare Viatris Inc (VTRS) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Xcel Energy Inc — how do they compare? Viatris Inc trades at $16.1 (market cap $18.69B), while Xcel Energy Inc trades at $78.52 (market cap $48.51B). The key difference: Xcel Energy Inc is far larger — about 2.6× Viatris Inc's market cap, and Xcel Energy Inc pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| VTRS | XEL | |
|---|---|---|
Market Cap | $18.69B | $48.51B |
Sector | Health | Utilities |
52-Week High | $17.86 | $83.91 |
52-Week Low | $9.49 | $71.75 |
Enterprise Value | $30.80B | $86.82B |
Dividend Yield | 2.95% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Xcel Energy (XEL) trades at $78.33, up 1.9% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, driven by infrastructure investment recovery. Revenue for 2025 was $14.67 billion with a net income margin of 15.28%. Analysts maintain a consensus buy rating with a $93.80 price target, highlighting growth from a $60 billion capital plan through 2030.
The outlook for XEL is positive due to projected EPS growth and rising electricity demand, but risks include regulatory pushback on rate increases and high capital expenditure. The stock offers stability with a dividend yield, yet valuation remains near historical highs, requiring careful monitoring of execution against its expansive investment strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
